Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Falk S, Anthoney A, Eatock M, Van Cutsem E, Chick J, Glen H, Valle JW, Drolet DW, Albert D, Ferry D, Ajani J. Falk S, et al. Among authors: drolet dw. Br J Cancer. 2006 Aug 21;95(4):450-6. doi: 10.1038/sj.bjc.6603267. Epub 2006 Aug 1. Br J Cancer. 2006. PMID: 16880795 Free PMC article. Clinical Trial.
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML. Ricart AD, et al. Among authors: drolet dw. Clin Cancer Res. 2008 Dec 1;14(23):7947-55. doi: 10.1158/1078-0432.CCR-08-0864. Clin Cancer Res. 2008. PMID: 19047127 Clinical Trial.
A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies.
Lee CP, de Jonge MJ, O'Donnell AE, Schothorst KL, Hanwell J, Chick JB, Brooimans RA, Adams LM, Drolet DW, de Bono JS, Kaye SB, Judson IR, Verweij J. Lee CP, et al. Among authors: drolet dw. Clin Cancer Res. 2006 May 1;12(9):2841-8. doi: 10.1158/1078-0432.CCR-05-1932. Clin Cancer Res. 2006. PMID: 16675579 Clinical Trial.
A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK; Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Goss G, et al. Among authors: drolet dw. Cancer Chemother Pharmacol. 2006 Nov;58(5):703-10. doi: 10.1007/s00280-006-0201-1. Epub 2006 Mar 10. Cancer Chemother Pharmacol. 2006. PMID: 16528532 Clinical Trial.
Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo-2-isoindolynl]-glutaric acid] in mice.
Desjardins J, Emerson DL, Colagiovanni DB, Abbott E, Brown EN, Drolet DW. Desjardins J, et al. Among authors: drolet dw. J Pharmacol Exp Ther. 2004 Jun;309(3):894-902. doi: 10.1124/jpet.103.064725. Epub 2004 Feb 24. J Pharmacol Exp Ther. 2004. PMID: 14982966
Pharmacokinetic Properties of DNA Aptamers with Base Modifications.
Gupta S, Drolet DW, Wolk SK, Waugh SM, Rohloff JC, Carter JD, Mayfield WS, Otis MR, Fowler CR, Suzuki T, Hirota M, Ishikawa Y, Schneider DJ, Janjic N. Gupta S, et al. Among authors: drolet dw. Nucleic Acid Ther. 2017 Dec;27(6):345-353. doi: 10.1089/nat.2017.0683. Epub 2017 Sep 29. Nucleic Acid Ther. 2017. PMID: 28961063 Free PMC article.
34 results